Femasys Inc. (FEMY) は上場企業です ヘルスケア セクターの Medical - Instruments & Supplies 業界で事業展開. 本社所在地は Suwanee, GA, アメリカ. 現CEOは Kathy Lee-Sepsick.
FEMY を有する IPO日 2021-06-18, 69 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $12.63M.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
